Industry
Biotechnology
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Loading...
Open
73.00
Mkt cap
13B
Volume
1M
High
73.48
P/E Ratio
-12.92
52-wk high
80.53
Low
71.56
Div yield
N/A
52-wk low
21.92
Portfolio Pulse from Benzinga Newsdesk
November 20, 2023 | 12:56 pm
Portfolio Pulse from Benzinga Newsdesk
October 27, 2023 | 5:43 pm
Portfolio Pulse from Benzinga Newsdesk
October 26, 2023 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
September 21, 2023 | 12:56 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2023 | 1:12 pm
Portfolio Pulse from Benzinga Newsdesk
September 07, 2023 | 3:47 pm
Portfolio Pulse from Benzinga Newsdesk
September 06, 2023 | 5:43 pm
Portfolio Pulse from Benzinga Insights
September 06, 2023 | 3:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 06, 2023 | 10:23 am
Portfolio Pulse from Lisa Levin
September 05, 2023 | 5:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.